SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-016151
Filing Date
2023-05-10
Accepted
2023-05-10 16:02:06
Documents
68
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 639662
2 logo_01.jpg GRAPHIC 14727
3 ex31-1.htm EX-31.1 11369
4 ex31-2.htm EX-31.2 11496
5 ex32-1.htm EX-32.1 8039
  Complete submission text file 0001493152-23-016151.txt   3921178

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mtnb-20230331.xsd EX-101.SCH 34570
7 XBRL CALCULATION FILE mtnb-20230331_cal.xml EX-101.CAL 50787
8 XBRL DEFINITION FILE mtnb-20230331_def.xml EX-101.DEF 91581
9 XBRL LABEL FILE mtnb-20230331_lab.xml EX-101.LAB 275658
10 XBRL PRESENTATION FILE mtnb-20230331_pre.xml EX-101.PRE 209250
62 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 518454
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

IRS No.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38022 | Film No.: 23906209
SIC: 2834 Pharmaceutical Preparations